In the original print version of the article listed above, there was a typographical error in Table 2 on page 103. The weight effects of GLP-1 receptor agonists should have been depicted as two downward-pointing arrows instead of one upward-pointing arrow.
TABLE 2.
Pharmacological Treatment Options in the Setting of Severe Insulin Resistance
| Medication Class | A1C Lowering* | Hypoglycemia Risk | Weight Effect | Ease of Use | Tolerability Issues | Relative Cost† |
| Treatment options that have been evaluated in patients with severe insulin resistance | ||||||
| GLP-1 receptor agonists | ↓↓ | ←→ | ↓↓ | Subcutaneous; once daily or once weekly | Nausea, vomiting | $$$ |
| Medication Class | A1C Lowering* | Hypoglycemia Risk | Weight Effect | Ease of Use | Tolerability Issues | Relative Cost† |
| Treatment options that have been evaluated in patients with severe insulin resistance | ||||||
| GLP-1 receptor agonists | ↓↓ | ←→ | ↓↓ | Subcutaneous; once daily or once weekly | Nausea, vomiting | $$$ |
*
Additional A1C lowering in previously treated patients; ↓ = 0.5–1%, ↓↓ = 1–1.5%, ↓↓↓ = 1.5–2%.
†
Relative cost per 30-day supply; $ = <$100, $$ = $100–299, $$$ = $300–750, $$$$ = >$750 based on average wholesale price (54).
The corrected table row appears below. The online version of the article was revsied on 19 April 2016 to reflect this change.
© 2016 by the American Diabetes Association.
2016
